Takeda’s FRUZAQLA reimbursed in Quebec for treatment of mCRC

Takeda (TAK) Canada announced that FRUZAQLA will now be reimbursed by Regie de l’assurance maladie for people in Quebec, under certain criteria, as a treatment for adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates, for available standard therapies. FRUZAQLA received market authorization by Health Canada in September 2024, followed by positive reimbursement recommendations by Canada’s Drug Agency and Institut national d’excellence en sante et services sociaux.